The DPX platform seems well suited for rapid, next gen vaccine development. $BIOV $BVAXF

$BIOV $BVAXF reports Phase 1B/2 data in recurrent ovarian cancer 3-year complete response in a patient Platinum-resistant ORR beats standard chemo Durable immune responses lasting years Survivin + PD-1 combo looks real

SET YOUR REMINDERS 🔔 Live today w/ BioVaxys Technology Corp. @ 4PM EST! $BIOV $BVAXF x.com/i/spaces/1LyxB…

Good morning

New week, new opportunities

$BIOV $BVAXF DPX keeps hitting different cancer types and actually getting responses - ovarian, bladder, breast all showing immune activity. That 3-year complete responder is exactly what catches pharma eyes. #Biotech #ClinicalTrials #CancerResearch #Microcap #Investing

$BVAXF 🇺🇸 $BIOV 🇨🇦 Has published positive clinical studies for their DPX platform effectiveness for 3 different types of cancer in the past 30 days: - Ovarian -Bladder - Breast This signals significant momentum with the development of this platform.

Happy Tuesday 😀

Join us Thursday @ 4:15PM EST for a live investor Q&A with BioVaxys Technology Corp.! $BIOV 🇨🇦 $BVAXF 🇺🇸 x.com/i/spaces/1MYxN…

$NVO $LLY $HIMS 🚨 BREAKING: NOVO NORDISK AD SPEND MORE THAN DOUBLE LILLY’S IN 2025, PER MEDIARADAR From Jan to Sep 2025: - $316m on Wegovy - $169m on Ozempic - $131m on Zepbound - $83m on Mounjaro Despite the massive ad spend imbalance, Zepbound overtook Wegovy last year,

Live now with BioVaxys Technology Corp.! $BIOV 🇨🇦 $BVAXF 🇺🇸 x.com/i/spaces/1MYxN…

Big piece here is the checkpoint resistant angle. Showing responses in patients who already failed PD 1 therapy is where the real clinical and commercial value sits, not just adding to frontline noise. $BIOV $BVAXF

Good morning

$NVO $LLY $HIMS 🚨 BREAKING: WEGOVY GLP-1 PILL HITS 44K PRESCRIPTIONS IN FIRST THREE WEEKS (IQVIA, DEUTSCHE) “Early data from Ro shows a higher proportion of men opting for the pill compared to injectables.” “Deutsche Bank analysts said in a Friday note that so far broader

Obesity is still a monster market, but the easy blue sky numbers are gone. $NVO and $LLY now have to prove they can grow volume fast enough to outrun price cuts, and whoever wins the pill race probably wins the next leg of the story.

We are very pleased to have been invited back to CEPI (the Coalition for Epidemic Preparedness Innovations) next month for a deeper scientific discussion of our DPX educating platform. CEPI cepi.net is a global partnership working to accelerate the development of

$LLY Eli Lilly targets India as global export hub amid booming Mounjaro sales, executive says $NVO $GPCR $VKTX $PFE $ABBV reuters.com/business/healt…

$LLY $NVO $HIMS 🚨 BREAKING: Retatrutide (12mg) trial participants lost an average of 28.7% of body weight after 68 weeks - Dropout rate due to adverse events: 18.2% (12mg) vs 12.2% (9mg) vs 6.2% for Zepbound’s highest dose in Phase 3 - Both reta doses showed ~75% reduction

$HIMS is acquiring Eucalyptus for ~$1.2B which adds an established telehealth platform across Australia, Japan, the UK, Germany and Canada. The deal brings ~$450M in run-rate revenue and ~775K customers accelerating Hims’ international scale.

Morning